Navigation Sage Therapeutics Axes GC After Drug-Pipeline Failures Force Cost-Cutting
Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment for Parkinson’s and Alzheimer’s.
Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment for Parkinson’s and Alzheimer’s.
